This study is about finding the best way to treat a lung infection called invasive aspergillosis (IA). IA is a serious infection caused by a fungus called Aspergillus, especially in people with weak immune systems. The study compares two treatments: Olorofim, a new antifungal medicine, and AmBisome®, an existing treatment, followed by the usual care. It aims to see which treatment is safer and more effective.

Many antifungal drugs have side effects and may not work well for everyone. Olorofim is promising because it works differently, can be taken by mouth, and is expected to have fewer side effects and drug interactions. This study is for people who can't use certain antifungal drugs or who haven't been helped by them. Participants must be 18 years or older and weigh more than 30 kg.

• Study Length: Participants will be part of the study for up to 28 days.
• Eligibility: Must have a specific type of Aspergillus infection and be able to take AmBisome®.
• Risks: Check for any allergies to the study medicine and no ongoing second fungal infections.